GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Tecvayli and Hernexeos might get speedy approval decisions.
The line-up is revealed to include Merck & Co and J&J itself.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
A phase 1 study of OKI-219 reads out imminently.
Bristol will test the bispecific in two new lung indications.
The latest onvansertib data, and an abrupt CEO departure, spook investors.
